Right. It goes right back to the heart of the matter, which is the lack of a science-based approach from the emerging markets and their own interpretation of OIE regulations and guidelines and lack of understanding of what some of the issues are—the way the diseases work, and the testing, their prevalence, and the scope of our country.
It really comes back to the lack of a science-based approach. I know that the OIE has their regulations and guidelines, but they are just that, guidelines, and countries can take it to the next level.